Background We aimed to measure the basic safety and tolerability of
Background We aimed to measure the basic safety and tolerability of different dosages of canakinumab versus placebo in sufferers with type 2 diabetes mellitus (T2DM). inhibition and T2DM disease, and lab abnormalities linked to haematology and biochemistry variables were reported. Basic safety was also analysed by age group ( 65, 65) and gender. Outcomes Average … [Read more…]